{
    "root": "69071a25-792d-4eec-a12a-1bb30c8fc881",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Austedo",
    "value": "20250228",
    "ingredients": [
        {
            "name": "DEUTETRABENAZINE",
            "code": "P341G6W9NB"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "POLYETHYLENE GLYCOL 2000000",
            "code": "5K3991GVWI"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POLYETHYLENE OXIDE 200000",
            "code": "11628IH70O"
        },
        {
            "name": "POLYETHYLENE OXIDE 5000000",
            "code": "3IG9032SAH"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "CARMINIC ACID",
            "code": "CID8Z8N95N"
        }
    ],
    "indications": "austedo xr® austedo® indicated adults treatment : chorea associated huntington ’ disease [ ( 14.1 ) ] tardive dyskinesia [ ( 14.2 ) ]",
    "contraindications": "austedo xr austedo recommended starting 12 mg daily ( 12 mg per day ) 6 mg twice daily ( 12 mg per day ) titrate weekly intervals 6 mg per day based reduction chorea tardive dyskinesia , tolerability , maximum recommended daily 48 mg ( 2.1 ) administer austedo xr without food once-daily doses ( 2.1 ) administer austedo food administer total daily dosages 12 mg two divided doses ( 2.1 ) swallow tablets whole ; chew , crush , break ( 2.1 ) switching patients tetrabenazine , discontinue tetrabenazine initiate austedo xr austedo following day . full prescribing information recommended conversion table ( 2.2 ) maximum recommended austedo xr austedo poor cyp2d6 metabolizers 36 mg per day ( 2.4 , 8.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "austedo xr austedo contraindicated patients : huntington ’ disease suicidal , untreated inadequately treated depression [ ( 5.1 ) ] . hepatic impairment [ ( 8.6 ) , pharmacology ( 12.3 ) ] . taking reserpine . least 20 days elapse stopping reserpine starting austedo xr austedo [ ( 7.2 ) ] . taking monoamine oxidase inhibitors ( maois ) . austedo xr austedo used combination maoi , within 14 days discontinuing therapy maoi [ ( 7.3 ) ] . taking tetrabenazine valbenazine [ ( 7.6 ) ] .",
    "indications_original": "AUSTEDO XR® and AUSTEDO® are indicated in adults for the treatment of:\n                  \n                     chorea associated with Huntington’s disease [see Clinical Studies (14.1)]\n                     \n                     tardive dyskinesia [see Clinical Studies (14.2)]",
    "contraindications_original": "AUSTEDO XR AUSTEDO Recommended Starting Dosage 12 mg once daily (12 mg per day) 6 mg twice daily (12 mg per day) Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg ( 2.1 ) Administer AUSTEDO XR with or without food in once-daily doses ( 2.1 ) Administer AUSTEDO with food and administer total daily dosages of 12 mg or above in two divided doses ( 2.1 ) Swallow tablets whole; do not chew, crush, or break ( 2.1 ) If switching patients from tetrabenazine, discontinue tetrabenazine and initiate AUSTEDO XR or AUSTEDO the following day. See full prescribing information for recommended conversion table ( 2.2 ) Maximum recommended dosage of AUSTEDO XR or AUSTEDO in poor CYP2D6 metabolizers is 36 mg per day ( 2.4 , 8.7 )",
    "adverseReactions_original": "AUSTEDO XR and AUSTEDO are contraindicated in patients:\n                  \n                     With Huntington’s disease who are suicidal, or have untreated or inadequately treated depression [see Warnings and Precautions (5.1)].\n                     With hepatic impairment [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].\n                     Taking reserpine. At least 20 days should elapse after stopping reserpine before starting AUSTEDO XR or AUSTEDO [see Drug Interactions (7.2\n                        \n                        )].\n                     Taking monoamine oxidase inhibitors (MAOIs). AUSTEDO XR and AUSTEDO should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI [see Drug Interactions (7.3\n                        \n                        )].\n                     Taking tetrabenazine or valbenazine [see Drug Interactions (7.6)]."
}